Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility

产肠毒素脆弱拟杆菌的获得与疾病易感性

基本信息

  • 批准号:
    10468700
  • 负责人:
  • 金额:
    $ 39.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-13 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Inflammatory bowel disease (IBD) and colonic malignancy are heterogeneous disease states that result from a complex interplay of host genetic and environmental factors. It is becoming increasingly clear that early events in development of the colonic microbiota influence host immunity, nutrition, and susceptibility to disease. Bacteroides fragilis comprises up to 2.5% of the human microbiota, and is often acquired within the first month of life. A subspecies of Bacteroides fragilis termed enterotoxigenic B. fragilis (ETBF) releases B. fragilis toxin (BFT), a zinc-dependent metalloprotease that causes a pro-inflammatory injury of the intestinal epithelium. ETBF has been implicated in the pathogenesis of IBD, colon tumorigenesis, acute diarrhea, and undernutrition in children. ETBF colonizes up to 20% of asymptomatic humans, suggesting that these individuals may incur an underappreciated long-term health risk from chronic carriage. We have demonstrated that competition for the B. fragilis niche within the colon is governed by strain-specific determinants including the Type VI bacterial secretion system. Further, the acquisition of protective strains of NTBF that restrict ETBF acquisition blunt the toxic effects of ETBF and thereby mitigate disease. The primary goal of this proposal is to examine neonatal acquisition of ETBF as a determinant of host susceptibility to disease. Through a comprehensive analysis of the genetic determinants of ETBF colonic niche establishment and the mechanisms by which BFT is expressed and released to act upon host cells, this study will define fundamental mechanisms that underlie ETBF-mediated disease. These studies will benefit from the use of a novel model of B. fragilis vertical transmission in which the temporal and genetic determinants of initial niche colonization by B. fragilis is examined in neonatal mice. It is anticipated that these studies will shed light on strategic opportunities for genetically informed probiotic-based approaches to modulate colonic disease through strain-specific niche competition, precluding the deleterious acquisition of ETBF that renders a host susceptible to disease.
项目总结 炎症性肠病(IBD)和结肠恶性肿瘤是由 寄主遗传和环境因素的复杂相互作用。越来越清楚的是,早期事件 结肠微生物区系的发育影响宿主免疫、营养和对疾病的易感性。 脆弱类杆菌占人类微生物群的2.5%,通常在第一个月内获得 生活的一部分。脆弱类杆菌的一个亚种,称为产肠毒素脆弱杆菌(ETBF),释放脆弱杆菌毒素 (BFT),一种锌依赖的金属蛋白酶,导致肠道上皮的促炎损伤。 ETBF与IBD、结肠肿瘤、急性腹泻和营养不良的发病机制有关。 在孩子们身上。ETBF在高达20%的无症状人类中定居,这表明这些人可能会导致 长期运输造成的长期健康风险未得到充分认识。我们已经证明了这一竞争 结肠内的脆弱杆菌生态位由菌株特异性决定因素控制,包括VI型细菌 分泌系统。此外,限制ETBF收购的NTBF保护性菌株的获得削弱了 ETBF的毒性效应,从而减轻疾病。这项提案的主要目标是检查新生儿 获得ETBF作为宿主对疾病易感性的决定因素。通过综合分析 ETBF结肠生态位建立的遗传决定因素及BFT形成机制 表达和释放作用于宿主细胞,这项研究将定义基础的基本机制 ETBF介导的疾病。这些研究将受益于一种新的脆弱芽孢杆菌垂直模型的使用。 脆弱杆菌初始生态位定植的时间和遗传决定因素是 在新生小鼠身上进行了检测。预计这些研究将揭示以下战略机遇 基于基因信息的益生菌通过菌株特异性生态位调节结肠疾病的方法 竞争,排除了有害的ETBF收购,使宿主容易感染疾病。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Bacteroides fragilis toxin expression enables lamina propria niche acquisition in the developing mouse gut.
脆弱拟杆菌毒素的表达能够在发育中的小鼠肠道中获得固有层生态位。
  • DOI:
    10.1038/s41564-023-01559-9
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    28.3
  • 作者:
    Hill,CraigA;Casterline,BenjaminW;Valguarnera,Ezequiel;Hecht,AaronL;Shepherd,ElizabethStanley;Sonnenburg,JustinL;BubeckWardenburg,Juliane
  • 通讯作者:
    BubeckWardenburg,Juliane
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Juliane Bubeck Wardenburg其他文献

Juliane Bubeck Wardenburg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Juliane Bubeck Wardenburg', 18)}}的其他基金

ADAM10 polymorphism in susceptibility to S. aureus disease
ADAM10 多态性对金黄色葡萄球菌病的易感性
  • 批准号:
    10649082
  • 财政年份:
    2023
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection
开发针对人群级别的金黄色葡萄球菌感染预防暴露前疫苗
  • 批准号:
    10483136
  • 财政年份:
    2022
  • 资助金额:
    $ 39.38万
  • 项目类别:
Enterotoxigenic Bacteroides fragilis in modulation of host immunity
产肠毒素脆弱拟杆菌对宿主免疫的调节作用
  • 批准号:
    10318195
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10366018
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10199312
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10577832
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility
产肠毒素脆弱拟杆菌的获得与疾病易感性
  • 批准号:
    10228659
  • 财政年份:
    2018
  • 资助金额:
    $ 39.38万
  • 项目类别:
Analysis of ADAM10 in infection-associated MODS
ADAM10 在感染相关 MODS 中的分析
  • 批准号:
    9379668
  • 财政年份:
    2017
  • 资助金额:
    $ 39.38万
  • 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
  • 批准号:
    10115783
  • 财政年份:
    2015
  • 资助金额:
    $ 39.38万
  • 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
  • 批准号:
    10576362
  • 财政年份:
    2015
  • 资助金额:
    $ 39.38万
  • 项目类别:

相似海外基金

NUFENOXOLE AND ANTIBIOTICS IN TREATMENT OF ACUTE DIARRHEA
纽芬诺和抗生素治疗急性腹泻
  • 批准号:
    4703610
  • 财政年份:
  • 资助金额:
    $ 39.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了